Home LiteratureArticle Details
PMID: 10393964 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption.

Yoshitake H, Rittling SR, Denhardt DT, Noda M

Abstract

Osteopontin is one of the major noncollagenous bone matrix proteins produced by osteoblasts and osteoclasts, bone cells that are uniquely responsible for the remodeling of mineralized tissues. Osteoclasts express the alphavbeta3 integrin, which is one of the receptors for osteopontin. Recent knockout studies revealed that noncollagenous bone matrix proteins are functionally important in regulation of bone metabolism. However, the significance of the presence of osteopontin in in vivo has not been known. We report here that osteopontin knockout mice are resistant to ovariectomy-induced bone resorption compared with wild-type mice. Microcomputed tomography analysis indicated about 60% reduction in bone volume by ovariectomy in wild-type mice, whereas the osteopontin-deficient mice exhibited only about 10% reduction in trabecular bone volume after ovariectomy. Reduction in uterine weight was observed similarly in both wild-type and osteopontin-deficient mice, indicating the specificity of the effect of osteopontin deficiency on bone metabolism. We propose that osteopontin is essential for postmenopausal osteoporosis in women. Strategies to counteract osteopontin's action may prove effective in suppressing osteoporosis.

MeSH Terms
Animals Bone Resorption/physiopathology,prevention & control Disease Models, Animal Female Humans Mice Mice, Inbred C57BL Mice, Inbred Strains Mice, Knockout Osteopontin Osteoporosis, Postmenopausal/physiopathology Ovariectomy Phosphoproteins/deficiency,physiology Sialoglycoproteins/deficiency,genetics,physiology Tibia/diagnostic imaging,pathology,physiopathology Tomography, X-Ray Computed
Chemicals
Phosphoproteins SPP1 protein, human Sialoglycoproteins Spp1 protein, mouse Osteopontin
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Yoshitake H
Department of Molecular Pharmacology, Medical Research Institute, Tokyo Medical and Dental University, 3-10 Kanda-Surugadai 2-Chome, Chiyoda-Ku, Tokyo, Japan.
Rittling S R
Denhardt D T
Noda M
References (40)
40 references, click to expand
  1. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro.
    J Bone Miner Res. 1998 Jul;13(7):1101-11 PMID: 9661074
  2. Mice lacking the type I interleukin-1 receptor do not lose bone mass after ovariectomy.
    Endocrinology. 1998 Jun;139(6):3022-5 PMID: 9607815
  3. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion.
    EMBO J. 1994 Mar 1;13(5):1189-96 PMID: 8131749
  4. The relationship of endogenous estrogen to bone density and bone area in normal postmenopausal women.
    Am J Epidemiol. 1986 Nov;124(5):752-61 PMID: 3766508
  5. The distribution of podosomes in osteoclasts cultured on bone laminae: effect of retinol.
    J Bone Miner Res. 1988 Oct;3(5):517-23 PMID: 3195364
  6. Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse.
    Endocrinology. 1990 Nov;127(5):2592-4 PMID: 2146111
  7. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice.
    Cell. 1991 Feb 22;64(4):693-702 PMID: 1997203
  8. Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts.
    Exp Cell Res. 1991 Aug;195(2):368-75 PMID: 1712731
  9. Recognition of osteopontin and related peptides by an alpha v beta 3 integrin stimulates immediate cell signals in osteoclasts.
    J Biol Chem. 1991 Oct 25;266(30):20369-74 PMID: 1939092
  10. Characterization of the functional stages of osteoclasts by enzyme histochemistry and electron microscopy.
    Anat Rec. 1991 Nov;231(3):298-315 PMID: 1662472
  11. Increased osteoclast development after estrogen loss: mediation by interleukin-6.
    Science. 1992 Jul 3;257(5066):88-91 PMID: 1621100
  12. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice.
    J Clin Invest. 1992 Oct;90(4):1622-7 PMID: 1383278
  13. High-resolution immunolocalization of osteopontin and osteocalcin in bone and cartilage during endochondral ossification in the chicken tibia.
    Anat Rec. 1992 Dec;234(4):479-92 PMID: 1456451
  14. Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl" (RGD)-containing protein.
    Endocrinology. 1993 Mar;132(3):1411-3 PMID: 8440195
  15. The menopause: health implications and clinical management.
    J Am Geriatr Soc. 1993 Apr;41(4):426-36 PMID: 8463532
  16. Ultrastructural immunolocalization of noncollagenous (osteopontin and osteocalcin) and plasma (albumin and alpha 2HS-glycoprotein) proteins in rat bone.
    J Bone Miner Res. 1993 Apr;8(4):485-96 PMID: 8475798
  17. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption.
    J Biol Chem. 1993 May 5;268(13):9901-7 PMID: 8486670
  18. Biochemical characterization of human osteoclast integrins. Osteoclasts express alpha v beta 3, alpha 2 beta 1, and alpha v beta 1 integrins.
    J Biol Chem. 1993 Aug 5;268(22):16737-45 PMID: 8344953
  19. Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells.
    J Biol Chem. 1994 Jan 7;269(1):711-5 PMID: 7506262
  20. Evidence that a non-RGD domain in rat osteopontin is involved in cell attachment.
    J Bone Miner Res. 1993 Dec;8(12):1499-506 PMID: 8304052
  21. Soluble alpha v beta 3-integrin ligands raise [Ca2+]i in rat osteoclasts and mouse-derived osteoclast-like cells.
    Am J Physiol. 1994 Feb;266(2 Pt 1):C376-81 PMID: 8141251
  22. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling.
    Science. 1994 Oct 21;266(5184):443-8 PMID: 7939685
  23. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period.
    Endocrinology. 1995 Jul;136(7):3054-61 PMID: 7789332
  24. Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. A cellular relationship among hematopoietic cells, osteoblasts, and osteoclasts mediated by stromal cells in bone marrow.
    Am J Pathol. 1995 Dec;147(6):1682-92 PMID: 7495293
  25. Antibody to beta3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat.
    Endocrinology. 1996 Mar;137(3):918-24 PMID: 8603604
  26. Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency.
    J Clin Invest. 1997 Apr 1;99(7):1699-703 PMID: 9120014
  27. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
    Cell. 1997 Apr 18;89(2):309-19 PMID: 9108485
  28. A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo.
    J Clin Invest. 1997 May 1;99(9):2284-92 PMID: 9151803
  29. The functional block of TNF but not of IL-6 prevents bone loss in ovariectomized mice.
    J Bone Miner Res. 1997 Jun;12(6):935-41 PMID: 9169353
  30. Integrin function in osteoclasts.
    J Endocrinol. 1997 Sep;154 Suppl:S47-56 PMID: 9379137
  31. Osteopontin expression and function: role in bone remodeling.
    J Cell Biochem Suppl. 1998;30-31:92-102 PMID: 9893260
  32. The effect of dichloromethylene diphosphonate, a pyrophosphate analog, on bone and bone cell structure in the growing rat.
    Anat Rec. 1979 Mar;193(3):439-62 PMID: 154858
  33. Comparison of the effects of 1,25-dihydroxycholecalciferol, prostaglandin E2, and osteoclast-activating factor with parathyroid hormone on the ultrastructure of osteoclasts in cultured long bones of fetal rats.
    Calcif Tissue Int. 1979;29(3):201-5 PMID: 117883
  34. 1,25-dihydroxycholecalciferol stimulates osteoclasts in rat bones in the absence of parathyroid hormone.
    Endocrinology. 1981 Jun;108(6):2293-301 PMID: 6894424
  35. Early menopausal changes in bone mass and sex steroids.
    J Clin Endocrinol Metab. 1985 Nov;61(5):905-11 PMID: 3930555
  36. The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats.
    Endocrinology. 1998 Mar;139(3):1411-9 PMID: 9492078
  37. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.
    Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597-602 PMID: 9520411
  38. Altered wound healing in mice lacking a functional osteopontin gene (spp1).
    J Clin Invest. 1998 Apr 1;101(7):1468-78 PMID: 9525990
  39. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
    Cell. 1998 Apr 17;93(2):165-76 PMID: 9568710
  40. osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
    Genes Dev. 1998 May 1;12(9):1260-8 PMID: 9573043
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
1999-07-06
Pages
8156-60
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC22204
Subset
IM
Grants
NIAMS NIH HHS · AR44434 · United States
NCI NIH HHS · CA72740 · United States
NIDCD NIH HHS · DC01295 · United States
Corrections
ErratumIn
-
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]